Opaleye Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Opaleye Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-240,000	Closed	-$1.34M	–	56
2022 Q1	$1.34M	Sell	240,000 -23,400	-9%	-$96.4K	0.42%	36
2021 Q4	$1.24M	Sell	263,400 -192,200	-42%	-$1.19M	0.26%	37
2021 Q3	$2.82M	Sell	455,600 -191,400	-30%	-$1.14M	0.53%	36
2021 Q2	$4.26M	Sell	647,000 -188,000	-23%	-$1.3M	0.71%	34
2021 Q1	$6.11M	Buy	835,000 +776,200	+1,320%	+$6.7M	0.9%	33
2020 Q4	$339K	Buy	+58,800	New	+$337K	0.04%	58

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Opaleye Management's AVEO Position: Q2 2022 in Review

Opaleye Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2022, closing a stake of 240,000 shares — an estimated $1.34M sold.

Opaleye Management first reported a position in AVEO in Q4 2020 and held it in 6 quarters. The position peaked at $6.11M in Q1 2021. 56 funds tracked by Wall St. Rank hold AVEO as of Q2 2022.

Opaleye Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
Opaleye Management sold 240,000 AVEO Pharmaceuticals, Inc. shares in Q2 2022, an estimated $1.34M.
Opaleye Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2020 and held it in 6 quarters.
Opaleye Management's AVEO Pharmaceuticals, Inc. position peaked at $6.11M in Q1 2021.
56 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2022.

Based on Opaleye Management's 13F filing for Q2 2022, filed 15 Aug 2022.